Twenty-four asthmatic subjects with stable asthma (19 women and five men) without systemic steroids and 18 healthy controls (nine women and nine men) were included. Asthma severity was scored according to the criteria of the Global Strategy for Asthma Management and Prevention

(GINA) (http://www.ginasthma.com) based on current therapy. Asthmatic subjects were grouped into atopics and non-atopics based on detection of specific IgE antibodies to house-dust mite, pets or pollen (grass or tree) and Rucaparib price on a clinical history suggestive of allergic response to those allergens. Symptoms were measured using the asthma control test (ACT). Prebronchodilator forced expiratory volume in 1 s (FEV1), FEV1 (%), prebronchodilator forced vital capacity (FVC), FVC (%) and ratio FEV1/FVC was measured by spirometry (Jaeger, Wuerzburg, Germany). Exhaled nitric oxide (FeNO) was measured using a NIOX-MINO® monitor (Aerocrine, Solna, Sweden). Patients continued with their usual inhaled corticosteroids (ICS) treatment which was Talazoparib chemical structure categorized as follows: < 500 μg/day beclomethasone dipropionate (BDP) or equivalent (n = 9), 500–1000 μg/day BDP or equivalent (n = 8) and > 1000 μg/day

BDP or equivalent (n = 7). Clinical parameters: age, sex, pulmonary function, asthma severity, atopic status, ACT, FeNO, ICS, number of years since diagnosis and history of smoking, rhinitis and nasal polyps were collected. Clinical Etofibrate parameters are summarized in Table 1. The sputum induction protocol from Pizzichini was followed, with some modifications [20]. Briefly, before sputum induction all subjects inhaled salbutamol (200 μg) via metered dose inhaler. Sputum was induced by 7-min inhalation

of hypertonic saline generated with an Omron Nebulizer (NE-U17-E). Subjects initially inhaled 3% saline, and if sufficient sputum was not produced the procedure was repeated with higher concentrations (4 and 5%). Subjects then expectorated into a sterile specimen cup. FEV1 was measured at baseline, after salbutamol inhalation and after each inhalation period, and the procedure was stopped if FEV1 fell by more than 10% or the patient coughed, wheezed or felt chest pain. Sputum was weighed, dispersed with 4 volumes of 0·1% dithiothreitol (Calbiochem Corp., San Diego, CA, USA) and incubated in a shaking waterbath at 37°C for 30 min. Cell viability was determined by Trypan blue exclusion. The differential count was obtained by counting 400 cells after Diff-Quik staining. If more than 5 × 105 cells were collected, 50% was frozen immediately for RNA extraction and the remaining 50% used for flow cytometry analysis. When fewer than 5 × 105 cells were collected, the sample was used for just one of these procedures.